Regular Article CLINICAL TRIALS AND OBSERVATIONS A phase 1 study evaluating the safety and tolerability of otlertuzumab, an anti-CD37 mono-specific ADAPTIR therapeutic protein in chronic lymphocytic leukemia
نویسندگان
چکیده
A phase 1 study evaluating the safety and tolerability of otlertuzumab, an anti-CD37 mono-specific ADAPTIR therapeutic protein in chronic lymphocytic leukemia John C. Byrd, John M. Pagel, Farrukh T. Awan, Andres Forero, Ian W. Flinn, Delva P. Deauna-Limayo, Stephen E. Spurgeon, Leslie A. Andritsos, Ajay K. Gopal, John P. Leonard, Amy J. Eisenfeld, Jeannette E. Bannink, Scott C. Stromatt, and Richard R. Furman
منابع مشابه
Regular Article CLINICAL TRIALS AND OBSERVATIONS Safety and activity of BTK inhibitor ibrutinib combined with ofatumumab in chronic lymphocytic leukemia: a phase 1b/2 study
Safety and activity of BTK inhibitor ibrutinib combined with ofatumumab in chronic lymphocytic leukemia: a phase 1b/2 study Samantha M. Jaglowski, Jeffrey A. Jones, Veena Nagar, Joseph M. Flynn, Leslie A. Andritsos, Kami J. Maddocks, Jennifer A. Woyach, Kristie A. Blum, Michael R. Grever, Kelly Smucker, Amy S. Ruppert, Nyla A. Heerema, Gerard Lozanski, Mona Stefanos, Brian Munneke, Jamie-Sue We...
متن کاملCLINICAL TRIALS AND OBSERVATIONS Results of a phase 1 clinical trial of thalidomide in combination with fludarabine as initial therapy for patients with treatment-requiring chronic lymphocytic leukemia (CLL)
Tumor necrosis factor (TNF) and vascular endothelial growth factor (VEGF) play an important role in the biology of chronic lymphocytic leukemia (CLL) cells. Thalidomide is a first-generation immunomodulating agent that down-regulates TNFand VEGF. We initiated a phase 1/2 clinical trial to determine the safety and efficacy of combining thalidomide with fludarabine in patients with treatmentnaı̈ve...
متن کاملRegular Article CLINICAL TRIALS AND OBSERVATIONS An open-label phase 2 trial of entospletinib (GS-9973), a selective spleen tyrosine kinase inhibitor, in chronic lymphocytic leukemia
Spleen tyrosine kinase (Syk) is a cytoplasmic protein tyrosine kinase that is predominantly expressed in cells of hematopoietic lineage. Syk functions normally to couple activated immunoreceptors to downstream signaling pathways. Syk signaling elicits a range of diverse biologic functions, including cellular development, function, proliferation, differentiation, and adhesion. In a normal, resti...
متن کاملCLINICAL TRIALS AND OBSERVATIONS A phase 1 trial of donor lymphocyte infusions expanded and activated ex vivo via CD3/CD28 costimulation
Donor lymphocyte infusions (DLIs) induce potent graft versus tumor (GVT) effects for relapsed chronic myelogenous leukemia (CML) after allogeneic stem cell transplantation (SCT) but are disappointing for other diseases. Disease resistance can occur if donor T cells are not appropriately activated in vivo. Ex vivo T-cell activation might overcome diseaseinduced anergy and augment GVT activity. W...
متن کاملCLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration
Alemtuzumab is a humanized anti-CD52 antibody licensed for refractory B-cell chronic lymphocytic leukemia (B-CLL), when given intravenously at 30 mg thrice weekly. However, the intravenous route is associated with infusion-related reactions and is inconvenient. We measured blood concentrations in 30 relapsed patients treated with intravenous alemtuzumab and in 20 patients from a previously untr...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره شماره
صفحات -
تاریخ انتشار 2014